Balancing the Treatment of Kaposi Sarcoma and Bullous Pemphigoid: A Therapeutic Challenge in a 63-Year-Old Male

平衡治疗卡波西肉瘤和类天疱疮:一位63岁男性患者的治疗挑战

阅读:1

Abstract

Kaposi sarcoma is a malignancy evolving from the lining of blood and lymphatic vessels. It is caused by the reactivation of human herpesvirus 8, often due to underlying immunosuppression. Classic Kaposi sarcoma occurs in Eastern European males greater than 50 years of age as painless violaceous papules to nodules. We report a case of a 63-year-old man with severe Kaposi sarcoma first diagnosed on the right medial foot with progressive involvement of upper and lower extremities. It was managed with monthly rounds of excisional cauterization, electrodesiccation, cryotherapy, and 5% imiquimod topical cream, leading to overall improvement and avoidance of amputation. However, a year later the patient presented with bullous pemphigoid on the left distal upper arm, suprapubic skin, and right and left pretibial regions. After three months of treatment with mycophenolate mofetil, prednisone, triamcinolone, doxycycline, and clobetasol, the patient's bullous pemphigoid stabilized. Hence, the simultaneous presentation of bullous pemphigoid and Kaposi sarcoma displays a unique problem in the management and treatment of dermatological conditions. Kaposi sarcoma is exacerbated through immunosuppression, whereas bullous pemphigoid treatment requires immunosuppressants. Extensive excisional therapy and cryotherapy for Kaposi sarcoma, alongside careful management of immunosuppressants for bullous pemphigoid, is critical for managing optimal care in concurrent cases. Further research should be performed to better understand the causal interplay of Kaposi sarcoma, imiquimod, bullous pemphigoid, and other dermatological issues requiring immunosuppressant treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。